Behind-the-Scenes a...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$3.32 0.04 | 1.38%
05/22/13 - 11:03 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.27 |
| 52 Week High | 4.05 |
| 52 Week Low | 2.07 |
| Avg. Daily Vol. (Mil) | 1.23 |
| Beta (3 year) | 1.48 |
| Share Related Items | |
| Mkt Cap (Mil) | 474.51 |
| Shares Out (Mil) | 145.11 |
| Float (Mil) | 99.08 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.50 |
| Current Ratio | 2.60 |
| LT Debt/ Equity | 0.66 |
| Total Debt / Equity | 0.91 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.18 |
| Price/Book | 14.79 |
| Price/Cash Flow | -8.80 |
| Per Share Data | |
| Earnings | -0.41 |
| Sales | 0.40 |
| Book Value | 0.22 |
| Cash Flow | -0.37 |
| Business Summary | |
|---|---|
| Avanir Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. | |
| General Information | |
| 20 Enterprise
Suite 200 Aliso Viejo, CA 92656 |
|
| www.avanir.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 225 | |
| CEO: Keith A. Katkin | |
| Short Interest | |
| Current Month (Mil) | 20.53 |
| Previous Month (Mil) | 20.28 |
| Short Interest Ratio (Days) | 14.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -64.60 |
| Return on Investments | -103.00 |
| Profitability | |
| Gross Margin | 96.90 |
| EBIT Margin | -89.40 |
| Profit Margin | -95.40 |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
Latest AVNR Headlines from TheStreet
- July Options Now Available For Avanir Pharmaceuticals (AVNR) 05.20.13 | 03:05 pm
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- 5 Stocks Facing an Earnings Short Squeeze 12.10.12 | 12:12 pm
- 5 Stocks Under $10 Set to Soar Higher 08.30.12 | 12:08 pm
- Avanir Pharmaceuticals' CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript) 08.14.12 | 02:08 pm
- Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript 08.08.12 | 09:08 pm
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
Press Releases for AVNR
- Avanir Pharmaceuticals To Participate In Two Upcoming Investor Conferences - PR Newswire 05.22.13 | 09:05 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2013 Second Quarter Financial Results And Conference Call - PR Newswire 05.01.13 | 08:05 am
- Avanir Pharmaceuticals Receives Positive CHMP Opinion For Approval Of NUEDEXTA In Europe - PR Newswire 04.26.13 | 07:04 am
- Avanir Pharmaceuticals Announces Appointment Of Corinne Nevinny To Board Of Directors - PR Newswire 03.11.13 | 04:03 pm
- AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY - PR Newswire 03.06.13 | 09:03 am
- AVANIR Pharmaceuticals To Paticipate In Two Conferences In March - PR Newswire 03.01.13 | 09:03 am
- Avanir Pharmaceuticals To Present At RBC Capital Markets' 2013 Global Healthcare Conference - PR Newswire 02.14.13 | 04:02 pm
- Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786 - PR Newswire 02.07.13 | 08:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call - PR Newswire 01.30.13 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.03.12 | 08:12 am
Partner Headlines for AVNR
- Avanir Pharmaceuticals Earnings: Here’s Why Investors Don’t Like These Results - Wall St. Cheat Sheet 05.08.13 | 07:05 am
- Pre-Market Most Active for Apr 26, 2013 : NOK, QQQ, ASML, BAC, MTU, RESI, JCP, BCS, FB, AVNR, ZNGA, SPNC - NASDAQ 04.26.13 | 12:04 pm
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- After-Hours Earnings Report for December 12, 2012 : AVNR, INTL - NASDAQ 12.12.12 | 07:12 pm
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel ... - GuruFocus 06.30.12 | 11:06 am
- Ultimate Stock Watch List for The Supreme Court's Health Care Ruling - Benzinga 06.28.12 | 09:06 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
